MedPath

Examination of the effectiveness and safety of multidisciplinary therapy with docetaxel for high-risk prostate cancer

Phase 1
Conditions
prostate cancer
Registration Number
JPRN-UMIN000023145
Lead Sponsor
Juntendo University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1.Males under the age of 20. 2. Refuses to give informed consent. 3. Refuses or is unable to have pelvic MRI or CT scan. 4. Without criteria for administration of docetaxel. 5. Deemed higher risk of administration of docetaxel by urologists or other physicians.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
biochemical recurrence-free survival (PSA)
Secondary Outcome Measures
NameTimeMethod
overall survival, safety of radiation therapy or surgery after administration of docetaxel
© Copyright 2025. All Rights Reserved by MedPath